Tumor angiogenesis factor (TAF) and its importance in determining a strategy for cancer chemotherapy are discussed. It is suggested that inhibition of RNA synthesis or increased RNA catabolism might interfere with the metabolism of solid tumor cells more so than in normal cells, and thus hinder angiogenesis and pursuant tumor growth by preventing the synthesis of the RNA component of TAF. An attempt is made to indicate potential models for anti-angiogenesis agents of this type. The drugs offered as initial prototypes for investigations along these lines are actinomycin D (which likely has antimetabolite and anti-angiogenesis activities), polyriboinosinic-polyribocytidylic acid (which likely has adjuvant and anti-angiogenesis activities) and ribonuclease (which in theory might be a purely anti-angiogenetic agent). It is noted that these models may turn out to be less than ideal as therapeutic agents due to problems of toxicity, metabolism, potency, or distribution, but nonetheless might serve to yield insights into the design of new cancer chemotherapeutic drugs. In addition, some evidence is cited suggesting that actinomycin D may be more effective against certain tumors when employed in lower, chronic dosages rather than its present use in "loading" dosages.
INTRODUCTION
This paper is an attempt to relate evidence from several disparate areas of investigation-from experiments designed to elucidate the mechanism of solid tumor neovascularization, and from investigations upon the ant,-tumor effects of the antibiotic actinomycin D (AcD), the synthetic polyribonucleotide polyriboinosinicpolyribocytidylic acid (poly I:C) and the enzyme ribonuclease. The intent is to suggest that recent findings support the possibility of relationships between the antitumor activities of these agents and the substance "tumor angiogenesis factor (TAF)" (1) . If any of the hypothetical relationships obtain, they have significant implications for evolving a strategy for cancer chemotherapy. It should be emphasized at the outset that the discussion, evaluation and proposals that follow are highly speculative in nature, and should not be construed to be directly supported by experimental data unless this is particularly specified. Some degree of circumstantiality of argument is due to the necessity of drawing upon studies that were not designed to answer questions pertinent to the subject of this paper.
TUMOR ANGIOGENESIS FACTOR
Several years ago, Judah Folkman and his colleagues published their initial report on the "Isolation of a Tumor Factor Responsible for Angiogenesis" (1) . Studies that support the existence of tumor angiogenesis factor (TAF) were later contributed by a British group (2) . As summarized in these and later reports, our knowledge concerning how a tumor recruits and maintains its blood supply (neovascularization) encompasses the following principles.
(1) Solid tumor growth requires neovascularization (1, 3, 4) . (2) In the absence of neovascularization, solid tumors cannot grow beyond the size of a spheroid perhaps 2-3 mm in diameter (3). (3) Neovascularization of solid tumors does not require direct cell to cell contact between tumor cells and endothelial cells (1, 2) .
The bioassay for TAF activity is somewhat inconvenient and requires large amounts of test material (1) . However, the possibility of more convenient in vitro assays is being explored (6) . TAF activity has been found in the cells of numerous animal and human tumors, including Wilm's tumor and choriocarcinoma (1, 5) . The only normal tissues in which TAF activity has been found are human placentas of 18 wk fetuses; regenerating normal tissue has been found to be TAF negative (5) . The experiments proving the existence of a specific angiogenetic factor were well controlled against nonspecific inflammation and vascular proliferation (1) . Confirmation of neovascularization induced by TAF preparations has been by light and electron microscopy (1, 7) and observation of radioactive nucleotide uptake in mitotic endothelial cells (4, 8) . Preliminary characterization of TAF preparations has yielded the following information.
(1) TAF isolated from tumor cell cytoplasm and nuclear nonhistone protein fractions contains varying amounts of associated ribonucleic acid (RNA) and carbohydrate (1, 5, 9, 10) . (2) TAF has an estimated molecular weight of 100,000 daltons or less (5, (9) (10) (11) (12) .
(3) TAF activity in the bioassay is destroyed by exposure to ribonuclease and some proteases (1, 5, 10 It has also been discovered that withdrawal of TAF is followed by the disappearance of newly formed capillaries (5, 9) . This is especially relevant and hopeful from the standpoint of potential therapeutic possibilities of "anti-angiogenesis." As a possible mode of "anti-angiogenesis" (i.e., inhibition of the activity and effects of TAF), Folkan's laboratory has attempted to generate antibodies against TAF. Their lack of success at this time has been attributed to the seeming lack of species specificity and the RNA content of TAF (5, 9) . Human tumor TAF induces endothelial cell mitoses in mice, rats, and rabbits (5) .
An interesting question is how TAF is related to the only other cellular product that has been found in all solid tumors examined. Unkeless et al. (13) Firstly, AcD is perhaps the most potent known anti-neoplastic agent on a molar basis (27) . AcD inhibits by as much as 75% tumor induction by some chemical carcinogens on mouse skin (28) . Hela cell tumors injected into mice that are immunosuppressed remain localized and small with AeD treatment, rather than forming large tumors as in untreated controls (29) . AcD is the drug of choice for the treatment of trophoblastic neoplasms (30) (31) (32) that tumor cells may recover from AcD inhibition quite quickly (25) .
POLY I: C Interest in the synthetic, double-stranded RNA polyriboinosinic-polyribocytidylic acid (poly I:C) as an antitumor agent arises from reports that the substance possesses activity against the growth of sexeral murine transplantable tumors, of both viral and nonviral origin (22, (41) (42) (43) (44) (45) (46) . The data of Levy et al. (41 ) indicated that the growth of a reticulum cell sarcoma, a lymphatic lymphoma, a fibrosarcoma and a human adenovirus-12-induced tumor was inhibited by injections of poly I:C.
Leukemic malignancies were least sensitive and the reticulum cell sarcoma was most sensitive to the drug's effects. In the case of the reticulum cell sarcoma and adenovirus-induced tumors, initiation of treatment even after the malignancy had grown to moderate size led to tumor regression, and some animals were free of disease two months after therapy ceased. With the, adenovirus-induced tumors, the initiation of poly I: C therapy yielded a very rapid "massive necrosis and sloughing" of tumor tissue in four of 10 animals, and marked regression in the other six. The authors mention the possibility that poly I: C may act upon blood vessels and aiffect the tumor blood supply. However, although many of the pathological changes attributed to poly I: C toxicity appear to be effects of the agent upon vascular endothelium (42) , there is no explanation for why it might affect tumor blood vessels more than "normal" vasculature.
Data have also been published recording the apparent cure of malignant melanoma B16 in mice, employing post-transplanation treatment with poly I:C (44).
Results indicating inhibition of the growth of the murine adenocarcinoma DBA in mice (45) and of two-stage skin carcinogenesis (46) by poly I:C therapy have appeared. Apparently, poly I:C is an anti-tumor agent with a surprisingly low degree of cytotoxcity (47) . Assessment of the effects of poly I:C on viral and chemical oncogenesis in vitro and in vivo have, however, yielded less clear cut findings. Poly I C enhances viral and chemical oncogenesis in certain cases and protects against it in others (22, 48-51). The general consensus is that the antitumor properties of poly I: C are unrelated to its ability to induce interferon (48) (49) (50) (51) (52) .
It has been suggested that poly I:C's anti-tumor activity is attributable to its known activation and stimulation of the host's immunological defence system (22, 43) . However, over the last few years, it has been demonstrated that poly I: C's anti-tumor activity is equivalent in both immunocompetent and thoroughly immunosuppressed animals (53) (54) (55) . In addition, poly I:C has been discovered to have a variable effect on humoral immunity in normal mice, and can suppress immunity in some animals (55) . This might explain the variable results in attempting to employ poly I:C against oncogenic viruses. In any case, it does not seem likely that poly I: C's anti-tumor activity is due primarily to its effects as an adjuvant.
Levy and Riley have shown that poly I: C strongly suppresses in vivo RNA and protein synthesis in several different murine tumors (56) . RNA and protein synthesis in normal tissues was inhibited or enhanced depending on the mouse strain tested. The inhibitory effect of poly I: C on macromolecular metabolism was greater in tumor than non-tumor tissues. Supporting evidence suggests direct cellular toxicity of some kind as the mechanism for the anti-tumor activity of poly I:C (57-60).
It has been demonstrated that some tumors show greatly increased transfer RNA methylase enzyme activity (61) (62) (63) (64) . These studies included viral-induced (62) and spontaneously arising tumors (63) . Concurrently, investigations concerning the mechanism of anti-tumor action of poly I: C have shown that this agent significantly inhibits tumor cell ribonucleotide reductase (65) and RNA methylases (66) . These latter authors suggest that "preferential inhibition of RNA methylation may be partially responsible for the anti-tumor activity of polyI: C (66) ." I would like to take this hypothesis (66) (69) . To the best of the author's knowledge, no studies concerning administration of ribonuclease to humans as an antineoplastic agent have been published. This is not surprising since there was no reason to even suspect this enzyme might affect the growth of tumor tissue. Also, for reasons already discussed, since ribonuclease could be expected to be an essentially pure "tumoristatic" agent, in single agent trials, it very well might seem ineffective. However, a Russian group has reported the inhibition of lymphosarcoma growth in rats by ribonuclease therapy (70, English abstract). There is little other evidence for anti-tumor activity on the part of ribonuclease employed as a single agent.
A most interesting study is that of Sartorelli (71 ) . In this investigation the survival of mice bearing sarcoma-I 80 ascites cell tumors was markedly enhanced by AcD and ribonuclease conjoint therapy at levels of each compound, which, when employed individually, displayed little or no effect. This series of experiments was carefully controlled, and therapy began 24 hr post-tumor implantation. Given the RNA content of TAF, this cooperativity of tumor inhibition by agents interfering with RNA metabolism takes on a promising light.
Certainly there is reason to hope that it may be possible to utilize ribonuclease activity in vivo, particularly in the case of hepatomas. At least by histochemical techniques, many tumor cells do not express ribonuclease activity (72) . A recent paper by Daoust is relevant (73) . Briefly, he found that the development of preneoplastic liver nodules was focally accompanied by loss of ribonuclease activity. The evidence appears convincing that a significant decrease in ribonuclease activity is a prerequisite or concomitant event in the origin of chemically-induced hepatomas in the rat (73) (74) .
It is interesting to consider whether host serum ribonuclease levels play any role in the defence against or reaction to tumor growth. The data on serum alkaline ribonuclease levels in patients having cancer is rather variable. However, a recent study selected about 100 patients in good general health with a range of histologic types of tumors, all of which were surgically resectable (75) . The observations were that the mean serum alkaline ribonuclease levels in patients with adenocarcinomas and squamous carcinomas were significantly higher than those of normal patients, or those with sarcomas or melanomas. The level of ribonuclease was not related to whether or not metastatic spread had occurred. These results, while far from conclusive, suggest that serum ribonuclease levels may possibly reflect the host's reaction to the presence of a growing tumor.
Certainly there is reason to hope that it may be possible to utilize ribonuclease as a cancer chemotherapeutic agent, and that its postulated effects on TAF-RNA might play an important role. If this potential usefulness of ribonuclease is realized, the likelihood of its employment as a relatively nontoxic, selective, homologous anti-tumor drug is a very real one. The technology for artificial synthesis of enzymes of this type and size is now available due to the efforts of Merrifield and his colleagues (76) .
